BioXcel Amends Credit Agreement; Deadline to Secure Repayment or Capital

What Happened
BioXcel Therapeutics, Inc. announced in an 8-K that on August 21, 2026 it entered into a Thirteenth Amendment to its Credit Agreement and Guaranty (the “Thirteenth Amendment”). The amendment requires the company to, on or prior to August 28, 2026 (an extension from the prior August 21 date), enter into one or more definitive agreements that either (A) result in repayment of all loans and other obligations under the Credit Agreement or (B) provide an alternative capital solutions transaction on terms acceptable to the lenders. The original Credit Agreement was dated April 19, 2022, and Oaktree Fund Administration LLC serves as administrative agent for the lenders.

Key Details

• Thirteenth Amendment executed: August 21, 2026.
• Deadline to enter into acceptable definitive agreements: on or prior to August 28, 2026 (extended from Aug 21, 2026).
• Required outcomes: (A) full repayment of all loan and other obligations under the Credit Agreement, or (B) an alternative capital solutions transaction acceptable to the lenders.
• Credit Agreement originally dated April 19, 2022; administrative agent is Oaktree Fund Administration LLC.

Why It Matters
The amendment sets a firm, near-term deadline for the company to secure repayment or an acceptable capital alternative, which is directly related to BioXcel’s financing and liquidity position. Investors should note the company must complete a lender-approved transaction by Aug 28, 2026; the terms and nature of any solution (repayment or alternative capital) could materially affect the company’s capital structure and operations. The full text of the Thirteenth Amendment is filed as Exhibit 10.1 in the 8-K for review.